South Korea
· Delayed Price · Currency is KRW KoBioLabs Statistics
Total Valuation
KoBioLabs has a market cap or net worth of KRW 99.00 billion. The enterprise value is 75.35 billion.
| Market Cap | 99.00B |
| Enterprise Value | 75.35B |
Important Dates
The next estimated earnings date is Friday, March 21, 2025.
| Earnings Date | Mar 21, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
KoBioLabs has 19.37 million shares outstanding. The number of shares has increased by 5.32% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 19.37M |
| Shares Change (YoY) | +5.32% |
| Shares Change (QoQ) | +1.29% |
| Owned by Insiders (%) | 29.91% |
| Owned by Institutions (%) | 0.44% |
| Float | 13.53M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.59 |
| PB Ratio | 2.42 |
| P/TBV Ratio | 2.46 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.96 |
| EV / Sales | 1.23 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -6.73 |
Financial Position
The company has a current ratio of 4.59, with a Debt / Equity ratio of 0.28.
| Current Ratio | 4.59 |
| Quick Ratio | 4.07 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.47 |
| Interest Coverage | -14.70 |
Financial Efficiency
Return on equity (ROE) is -13.24% and return on invested capital (ROIC) is -8.06%.
| Return on Equity (ROE) | -13.24% |
| Return on Assets (ROA) | -6.38% |
| Return on Capital (ROIC) | -8.06% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.55 |
| Inventory Turnover | 7.82 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -35.12% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -35.12% |
| 50-Day Moving Average | 6,059.50 |
| 200-Day Moving Average | 7,151.03 |
| Relative Strength Index (RSI) | 37.88 |
| Average Volume (20 Days) | 59,565 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KoBioLabs had revenue of KRW 61.29 billion and -9.47 billion in losses. Loss per share was -497.17.
| Revenue | 61.29B |
| Gross Profit | 41.18B |
| Operating Income | -11.33B |
| Pretax Income | -8.54B |
| Net Income | -9.47B |
| EBITDA | -9.04B |
| EBIT | -11.33B |
| Loss Per Share | -497.17 |
Balance Sheet
The company has 57.56 billion in cash and 16.50 billion in debt, giving a net cash position of 41.06 billion or 2,119.29 per share.
| Cash & Cash Equivalents | 57.56B |
| Total Debt | 16.50B |
| Net Cash | 41.06B |
| Net Cash Per Share | 2,119.29 |
| Equity (Book Value) | 58.28B |
| Book Value Per Share | 2,109.61 |
| Working Capital | 53.57B |
Cash Flow
In the last 12 months, operating cash flow was -7.75 billion and capital expenditures -3.43 billion, giving a free cash flow of -11.19 billion.
| Operating Cash Flow | -7.75B |
| Capital Expenditures | -3.43B |
| Free Cash Flow | -11.19B |
| FCF Per Share | -577.52 |
Margins
Gross margin is 67.18%, with operating and profit margins of -18.49% and -15.45%.
| Gross Margin | 67.18% |
| Operating Margin | -18.49% |
| Pretax Margin | -13.93% |
| Profit Margin | -15.45% |
| EBITDA Margin | -14.75% |
| EBIT Margin | -18.49% |
| FCF Margin | n/a |
Dividends & Yields
KoBioLabs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.32% |
| Shareholder Yield | -5.32% |
| Earnings Yield | -9.73% |
| FCF Yield | -11.30% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
KoBioLabs has an Altman Z-Score of 0.62. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.62 |
| Piotroski F-Score | n/a |